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Abstract
MicroRNAs (miRNAs) are a class of small non-coding RNA molecules of approximately 
22 nucleotides that regulate gene expression at the post-transcriptional level. Alterations 
in miRNA expression patterns correlate with a wide spectrum of pathological conditions, 
including cancer. miRNA profiling was mostly performed, in solid tissues, obtained 
by invasive diagnostic procedures. However, miRNAs in biofluids, such as serum and 
plasma, show high stability resulting from the formation of complexes with specific 
protein or incorporation within circulating exosomes or other microvesicles. Circulating 
miRNAs could be reliable biomarkers for early-stage cancer diagnosis, prognosis and 
response to therapy. In this chapter, we analyze the major pre-analytical and analytical 
challenges in experimental design for circulating miRNA detection, focusing on exosome 
fraction and microarray-based approach.
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1. Introduction
MicroRNAs (miRNAs) are small evolutionary conserved non-coding RNAs of 19–25 nucleo-
tides that bind to the 3′-untranslated region (3’-UTR) of target mRNAs, resulting in a negative 
regulation of gene expression by suppressing translation or causing mRNA degradation [1]. 
The complex miRNA network plays an important role in the regulation of cellular processes 
such as development, proliferation, differentiation and apoptosis. Significant changes of tis-
sue miRNA “signatures” occur in various diseases, including cancer [2–4]. More than 50% 
of human miRNAs are mapped to chromosomal region of genomic instability due to extensive 
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repetitive sequences resulting in structural mutations (deletion, duplication and transloca-
tion) during tumor development [5]. Regulation of miRNA expression is an important mecha-
nism by which tumor-suppressor proteins and oncogenic proteins exert some of their effects. 
A decrease or mutation in tumor-suppressor miRNAs can lead to overexpression of oncogenic 
proteins, in contrast to an overexpression of oncogenic miRNAs which can reduce expres-
sion of tumor suppressors. For example, tumor suppressor of the let-7 family targets RAS 
oncogene, which is involved in cell growth, differentiation and survival; reduced expression 
of let-7 miRNAs correlates with poor survival in many cancers [6]. In contrast, oncogenic miR-
NAs in the cluster miR-17-92, comprising six miRNAs (miR-17, miR-18a, miR-19a, miR-20a, 
miR-19b-1 and miR-92a-1), inhibits PTEN to activate AKT signaling and promote cancer cell 
survival [7].
miRNAs have been considered promising candidates as diagnostic and prognostic biomark-
ers for the strong correlation between expression patterns of miRNAs and disease status and 
for the differences between normal and cancer tissues. This reflects the current evidence that 
some miRNAs are overexpressed or downregulated exclusively or preferentially in certain 
cancer types.
Although miRNA profiling of tumors has been reported in solid tissues, obtained by invasive 
procedures, as an excellent prognostic test [8], routine biopsies from any organ for miRNA 
profiling are not practical options. Different studies suggest that circulating miRNAs are reli-
able indicators of pathological change because of their stability and protection against RNase 
digestion resulting from the formation of complexes with specific protein or incorporation 
within circulating exosomes or other extracellular vesicles (EV) [9]. In this context, accumulat-
ing evidence suggests that tumor cells are able to alter the function of both local and distant 
normal cells, thereby promoting tumor growth and metastasis, through the transfer of EV 
cargo [10]. miR-21, which targets the tumor-suppressor gene PTEN and programmed cell 
death 4 (PDCD4), is one of the first discovered and most investigated circulating miRNAs. Its 
upregulation seems to be of diagnostic and prognostic value in a variety of solid and hemato-
logical malignancies. High serum levels of miR-21 were strongly associated with lymph node 
metastasis, advanced-stage clinical disease and poor survival [11]. In patients with ovarian 
cancer, high serum levels of miR-34a were associated with lymph node disease and distant 
metastases [12].
Also, in patients with prostate cancer, plasma levels of miR-21, miR-141 and miR-221 were 
significantly higher in patients with metastases as compared to patients with localized or 
locally advanced-stage disease [13].
Currently, a variety of miRNA detection methods, including northern blotting, in situ hybrid-
ization, quantitative reverse transcription PCR (qRT-PCR), microarray and deep sequencing, 
are commonly used [14]. However, miRNA profiling in biofluid samples is affected by a range 
of pre-analytical and analytical challenges in experimental design, from sample collection to 
profiling and data analysis (Figure 1). In this chapter, we will propose a workflow for exosomal 
miRNA detection from sera samples using the Affymetrix GeneChip microarray platform as a 
powerful molecular approach for biomarker discovery to translate into clinical practice.
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2. Methodological challenges in miRNA profiling design
2.1. Sample collection
Blood sample processing has a substantial impact on the results of miRNA profiling. During 
blood collection, it is important to avoid cellular contamination and hemolysis that can occur 
during phlebotomy as miRNAs derived from red and white blood cells risk to mask the inten-
sities of truly circulating miRNA species. Residual platelets and microparticles can also affect 
the miRNA profile so an additional centrifugation is recommended prior to freezing samples. 
Moreover, biofluidics contain inhibitors of the reverse transcriptase and polymerase enzymes 
that can inhibit the enzymatic reactions in RT-qPCR so it is important to minimize the car-
ryover of inhibitors into the RNA.
In our protocol, blood samples were collected and processed according to the national cancer 
institute (NCI’s) Early Detection Research Network (EDRN) standard operating procedures 
for the collection and preparation of serum [15].
Whole blood samples were collected in red-top vacutainer tubes. Blood samples were incu-
bated at room temperature for 30 min to allow complete coagulation. Coagulated samples 
were then centrifuged at 1500 × g for 20 min at room temperature to separate serum. The 
serum was transferred to new cryotubes with care so as to not to disturb the red blood layer 
and then centrifuged for 5 min at 3000 × g to remove cells. Aliquots of 1.5 ml of superna-
tant containing the cell-free serum were stored in cryotubes at −80°C until RNA extraction. 
Hemolyzed samples were excluded from further analysis.
2.2. Exosome isolation and characterization
The established standard for exosome isolation is ultracentrifugation [16]. However, this 
method cannot discriminate between exosomes and other microvesicles because different vesi-
cles of similar size as well as protein aggregates can co-sediment at 100,000 × g.
Recently, methods claiming fast and simple exosome-purification procedures without ultra-
centrifugation are commercially available by various firms that use polymer-based precipita-
tion or immune capture by antibody-coated beads.
However, according to the International Society for Extracellular Vesicles (ISEV) the separa-
tion of non-vesicular entities, such as protein complexes, from EV is not fully achievable by 
Figure 1. Summary of workflow in designing miRNA profiling from blood serum.
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common EV isolation protocols, including centrifugation protocols or commercial kits. On 
the other hand, a list of EV-specific markers that distinguish subsets of EVs from each other 
is not proposed [17]. The ISEV provides minimal requirements to claim the presence of EV in 
pellets isolated from different methods. They suggested assessing the protein composition in 
at least a semi-quantitative manner in any EV preparation (Western blots, flow cytometry or 
mass spectrometry techniques). Size distribution of EVs, such as nanoparticle-tracking analy-
sis (NTA), dynamic light scattering or resistive pulse sensing, needs to be analyzed. However, 
the values acquired with these techniques should be compared with TEM, AFM or other 
microscopy techniques, since they do not distinguish membrane vesicles from co-isolated 
non-membranous particles of similar size.
In our laboratory, serum exosomes underwent isolation by miRCURYTM Exosome Isolation 
Kit (Exiqon, Vedbaek, Denmark). The process is based on capturing water molecules which 
otherwise form the hydrate envelope of particles in suspension. The samples (1.5 ml) thawed 
on ice or at 4°C, were mixed with a precipitation solution in order to reduce the hydration of 
the particles. This allows precipitation of the subcellular particles below 100 nm with a low-
speed centrifugation step after incubation at 4°C for 1 h. The last pellet, containing exosomes, 
was resuspended using 240 μL of the provided resuspension buffer and used for further RNA 
extraction or stored at −20°C.
NTA was performed using a NanoSight LM10-HS microscope equipped with NTA software 
v3.1 (NanoSight Ltd., UK). Background was extracted and the automatic setting for minimum 
expected particle size, minimum track length and blur settings was employed. Each sample 
was diluted at 1:10,000 in sterile-filtered PBS (Sigma, USA). A video of typically 60 s duration 
was made, with a frame rate of 30 frames per second, and particle movement was analyzed 
by NTA software. Only measurements with >1000 completed tracks were analyzed (Figure 2).
We also have used 20 μL of human CD63 coated beads (Thermo Fisher Scientific, Inc) per 50 μL 
sample in order to isolate CD63 positive sub-populations of exosomes from total exosome iso-
lations derived from serum samples. The isolated exosomes were stained for typical exosome 
markers, such as CD63, and CD9 was analyzed with the Attune NxT Flow Cytometer (Thermo 
Fisher Scientific, Inc.) (Figure 3).
2.3. RNA purification
RNA extraction method is another important issue in miRNA profiling as the exosomal RNA 
pattern is highly correlated with the sample source. The principles for isolating miRNA for 
profiling are, in general, the same for isolation of total RNA, except that miRNA isolation pro-
tocols are adapted to retain the small RNA fraction. In different studies describing exosome 
RNA, a number of alternative RNA extraction methods have been used, including phenol-
based techniques, combined phenol and column-based approaches and pure column-based 
techniques [18–22].
For RNA purification from exosomes, we used the miRCURYTM RNA Isolation Kit (Exiqon, 
Vedbaek, Denmark) that is based on spin column chromatography using a proprietary resin 
as the separation matrix. First, membrane particles and cells were lysed using the lysis solu-
tion and then proteins were precipitated using the provided protein precipitation solution. 
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Isopropanol was added to the supernatant and the solution was loaded onto a spin column. 
Thus, only molecules of RNA will bind to the resin, while proteins will be removed in the 
flow through. The RNA bound to the column was then washed with provided wash solu-
tion in order to remove any remaining impurities and then eluted with 100 μL of RNase 
free water.
We also evaluated miRNA recovery from serum samples by the use of the exogenous syn-
thetic miRNA cel-mir-39 (Applied Biosystems, Inc.) as standard control. For this procedure 
during RNA isolation, a known amount of cel-mir-39 (25 fmol) was spiked in each serum 
sample after the denaturation step. Consistent and homogeneous miRNA recovery leads to 
cel-miR-39 levels that are similar in all samples. A standard curve was generated using five 
ten-fold dilution of cel-miR-39 (1.4 × 10–4–1.4 × 10–8 ng) processed in parallel with qRT-PCR of 
experimental samples. The copy number of spiked cel-miR-39 was estimated, plotting Ct val-
ues, versus the copy number of the synthetic miRNA. The recovery of the synthetic miRNA 
is considered consistent if cel-miR-39 Ct values are within the range of acceptability (≤2 × 
standard deviation) in replicate isolations.
2.4. RNA quantification and quality control
Exosomal RNA purity was assessed by Nanodrop ND-1000 UV spectrometer (Thermo 
Scientific, Wilmington, DE) at the absorbance of 230, 260 and 280 nm. RNA samples extracted 
Figure 2. Extracellular vesicle NanoSight data. Example NanoSight NTA video frame (A), NanoSight NTA particle size/
concentration for 3 different miRCURYTM Exosome Isolation Kit recovered exosome pellets (B).
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using the miRCURYTM method produced RNA concentrations above the lower detection limit 
of 2 ng/μL of the NanoDrop instrument and less than 10 ng/μL. Moreover, the miRCURYTM 
RNA isolation method showed a high average A260/280 ratio (1.9 ± 0.1) but low average 
Figure 4. Bioanalyzer analysis of serum exosomal small RNA. Exosome total RNA derived from serum was analyzed 
using Small RNA Kit in an Agilent 2100 Bioanalyzer. The electropherograms show the size distribution in nucleotides 
(nt) and fluorescence intensity (FU) of ladder (A) and exosome total RNA (B). The peak at 4 nt is an internal standard. 
The Small RNA region is visible in the interval of 0–150 nucleotides, including the miRNAs in the sizes between 10 and 
40 nucleotides.
Figure 3. Flow analysis on exosome sub-populations (A). Exosomes isolated with CD63 showed that serum-derived 
exosome in our samples express high level of CD63 marker (82.6%) and a moderate level of CD9 markers (32.8%) (B).
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A260/230 ratio (<2.0). These values are consistent and acceptable in samples containing very 
low amounts of RNA, as biofluid samples.
Because of the absence of 18S and 28S rRNA species in serum, the quality of isolated RNA 
samples might not be assessable by means of RNA integrity number (RIN), as a rule for total 
RNA samples to use for microarray procedures. On this basis, we used the Agilent Small RNA 
assays that are able to resolve fragments in the range 0–150 nucleotides (Figure 4).
3. MiRNA profiling and data analysis
miRNA expression profiling has allowed the identification of miRNAs that are involved in 
many biological processes, including organism development and establishment and main-
tenance of tissue differentiation [23, 24]. Thus, miRNAs are being explored as elements for 
cell-fate reprogramming in stem-cell applications or as biomarkers for identifying the origin 
of cancers of unknown primary sites. The expression pattern of miRNAs is widely different 
being tissue specific and related to developmental stages. Measuring miRNA expression can 
also be useful for system-level studies of gene regulation, especially when miRNA profiles 
are integrated with mRNA profiling. Circulating extracellular miRNAs, including exosome 
miRNA, are quantifiable in a range of specimen types including serum, plasma, urine and 
formalin-fixed tissue block. Hence, they are important as non-invasive biomarkers for many 
molecular diagnostic applications, including cancer [25, 26], cardiovascular and autoimmune 
diseases [27] and forensics [28]. Table 1 shows new and promising miRNAs as potential bio-
markers for diagnosis and prognosis of different cancers.
3.1. General consideration for high-throughput miRNA profiling
The yield of RNA extracted from biofluids is usually very low, in the order of 1–10 ng. If we 
consider that miRNAs represent only 0.01% of total RNA, the strategies used for their detec-
tion and quantification are crucial. Some general consideration must be made in high-through-
put miRNA profiling. First, the length of mature miRNA (19–25 nucleotides) is too low to 
allow annealing to the traditional primers during the reverse transcription step. Second, unlike 
mRNAs, miRNAs lack poly(A) tail, a region frequently used to anneal complementary and 
universal primers for RNA enrichment or reverse transcription. Third, miRNAs exist in differ-
ent isoforms, so-called isomiRs, that are functional and evolutionarily important and, inside 
the same family (e.g., the let-7 family), can differ by a single base to the reference miRNA 
sequence. Depending on the goals of an miRNA profiling experiment, measurement of differ-
ent forms may be required, even if the large majority of miRNAs typically show only modest-
length heterogeneity. Another challenge for miRNA high-throughput profiling is variance in 
miRNA GC content that is reflected in different melting temperatures (Tm) of annealing reac-
tions. To date, three major approaches are used for miRNA profiling: quantitative reverse tran-
scription PCR (qRT-PCR), hybridization-based methods (microarrays) and next-generation 
sequencing (NGS) (RNA-seq). Microarrays were among the first hybridization-based methods 
to be used for parallel analysis of large numbers of miRNAs.
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3.2. Microarray miRNA profiling
Microarrays provide a high-throughput approach to profile all annotated miRNAs, in differ-
ent types of samples including biological fluids. This method is relatively less expensive than 
others, such as qRT-PCR and next-generation sequencing (NGS). Moreover, the integrated 
analysis of the expression profile of miRNAs and their target genes, together with the analysis 
of each miRNA gene target pathway, is able to provide information on the function of each 
miRNA for a given sample. The technique generally begins with the enzymatic or chemical 
marking of targets followed by their hybridization to oligonucleotides fixed on a solid sup-
port. The signal generated by each probe is detected by a scanner and analyzed by specific 
software able to process the signal intensity. The variables related to the method include the 
Cancer Samples miRNAs Types of 
biomarkers
Reference
Head and neck Plasma miR-21 qRT-PCR D [29]
Lung cancer Serum miR-182, miR183, miR-
210, miR-126
qRT-PCR D [30]
Serum miR-125b qRT-PCR R [31]
Breast cancer Serum miR-1, miR-92a, miR-
133a, miR-133b
Microarray D [32]
Serum miR-125b qRT-PCR R [33]
Ovarian cancer Serum miR-34a P [12]
Prostate cancer Plasma miR-21, miR-141, miR-221 qRT-PCR D [13]
Gastric cancer Serum miR-1, miR-20a, miR-27a, 
miR-34, miR-423-5p
qRT-PCR D [34]
Renal cancer Serum miR-378, miR-451 qRT-PCR D [35]
Pancreatic cancer Serum miR-16 and miR-196a qRT-PCR D [36]
miR-21 qRT-PCR R [37]
Colorectal cancer Plasma miR-409-3p, miR-7, 
miR-93
qRT-PCR D [38]
miR-126 qRT-PCR R [39]
Hepatocellular cancer Exosome miR-101, miR-221, miR-
221, miR-224
qRT-PCR D [40]
Melanoma Serum miR-221 qRT-PCR D, P [41]
Lymphoma Serum miR-221 qRT-PCR P [42]
Leukemia Exosome miR-29a qRT-PCR P [8]
D = diagnostic; P = prognostic; R = response predictor.
Table 1. Circulating miRNAs as potential biomarkers in different cancers.
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different hybridization efficiencies of each probe, due to their different content in GC, the dif-
ferent melting temperature, due to the reduced size of miRNAs, the bias due to the enzymatic 
labeling and the relative low dynamic range. Microarray-based methods generally require a 
larger amount of starting material than qRT-PCR, and it can be challenging to develop probes 
and hybridization conditions that work well to detect many different miRNAs at once [43, 
44]. miRNA profiling by NGS platforms may be the most promising approach, as it largely 
avoids many miRNA measurement pitfalls [45]. However, NGS remains expensive and labor 
intensive, both in the sample preparation and data analysis.
3.3. Affymetrix GeneChip microarray platform
To date, oligonucleotide-miRNA microarray analysis is the most common high-through-
put technique for assessment of disease-specific expression of hundreds of miRNAs. The 
Affymetrix GeneChip® miRNA microarrays platform provides the most sensitive, accurate 
and complete measurement of small non-coding RNA transcripts involved in gene regula-
tion. It represents miRNA sequences from all organisms present in miRBase (http://www.
mirbase.org), as well as small nucleolar RNAs (snoRNA) and small Cajal body-specific RNAs 
(scaRNA) included in snoRNABase (http://www.snorna.biotoul.fr/) and Ensembl (http://
www.ensembl.org). This platform has been used in our laboratory with success to profile 
exosome non-coding RNA from serum samples (unpublished data, manuscript in prepara-
tion). The protocols for non-coding RNA profiling include the use of the Affymetrix FlashTag 
Biotin HSR RNA Labeling Kit (Affymetrix, Santa Clara, CA, USA) and the detection by flu-
orescent emission. Total RNA samples or total RNA samples enriched for low molecular 
weight (LMW) RNA were starting materials. The process begins with a poly(A) tailing reac-
tion followed by the ligation of a biotinylated signal molecule to the target RNA samples. 
The labeled RNA samples are included in the hybridization mix and hybridized overnight 
to Affymetrix GeneChip miRNA arrays (Affymetrix, Santa Clara, CA, USA), followed by a 
procedure to wash, stain and scan the array to acquire probe cell intensity data (CEL file). To 
date, the GeneChip miRNA 4.0 array is the updated array designed to interrogate all mature 
miRNA sequences contained in miRBase release 20, including 30,424 probe sets, covering 203 
organisms and requiring low sample input (130–1000 ng total RNA). CEL files analysis by the 
Expression Console Software coupled with Transcriptome Analysis Console (TAC) Software 
(Affymetrix, Santa Clara, CA, USA) leads to a simple, fast and free analysis for Affymetrix 
GeneChip expression arrays.
3.4. Analysis of raw data
Raw data processing begins with quality control analysis by assessing the performance of 
internal controls and analyzing replicates to detect biases. For example, microarrays have 
well-known geographic biases, because some areas of the array perform differently from oth-
ers. Data normalization, which is the next step after quality assessment, is crucially for obtain-
ing accurate results [46]. The goal of normalization is to adjust the data to remove variation 
across samples not related to the biological condition and therefore allowing the identification 
of relevant biological differences. The normalization step is particularly important because 
some of the discrepancies between miRNA profiling studies are in part due to the application 
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of different normalization approaches. GeneChip array data are normalized by the use of a 
tool that uses Robust Multichip Analysis (RAM) plus detection above background (DABG) 
algorithms, as default analysis. RAM is a robust linear normalization model, to minimize the 
effect of probe-specific affinity differences, and consists of three steps: background adjust-
ment, quantile normalization and summarization. DABG is a detection metric generated by 
comparing perfect match probes to a distribution of background probes.
miRNA profiling experiments typically involve comparisons between two or more groups, 
and therefore the next stage of analysis is usually the calculation of differential miRNA 
expression between groups. The degree of fold difference that constitutes a meaningful differ-
ence depends on the experimental context, although it is always useful to assess the statistical 
significance and false discovery rate that is associated with the differential miRNA expres-
sion. This comparison yields a p-value, which is, then, combined into a probe set level p-value 
using the Fischer equation. Statistical analysis is performed using TAC and a fold change of 
two is commonly adopted to describe the signal changes between groups.
3.5. Circulating miRNA profiling challenges
Circulating exosome miRNAs are surprisingly stable and show distinct expression profiles 
among different fluids. Given the instability of most RNA molecules in the extracellular envi-
ronment, the presence and apparent stability of miRNAs in body fluids such as serum and 
other body fluids, that are known to contain ribonucleases, suggest that secreted miRNAs 
are packaged in some manner to protect them against RNase digestion. miRNAs could be 
shielded from degradation by packaging in lipid vesicles, like exosomes, in complexes with 
RNA-binding proteins or both [47]. This view supports the idea that extracellular miRNAs 
are prepared for export in one cell. They can be recognized, taken up and utilized by another 
cell, working as mediators of cell-cell communication [48–50]. The growing interest in devel-
oping circulating miRNAs as blood-based biomarkers requires very careful consideration of 
the effects of various pre-analytical procedures, such as handling and storage conditions of 
the sample before processing, which can affect the reliability and reproducibility of circulating 
miRNA quantification. The main technical difficulty to study miRNA expression profiles is the 
efficient extraction of miRNAs from biological samples, because of their small size and their 
attachment to lipids and proteins. The use of commercial extraction kits has become available to 
optimize the extraction of small RNAs and normalize sample-to-sample variations in isolation 
procedures. Therefore, it is important to establish standardized protocols for blood collection, 
sample storage conditions, inclusion of exogenous and endogenous miRNA controls for each 
clinical sample and standardized calculations for normalization of the results to ensure the 
reproducible and accurate quantification of circulating miRNA levels so that miRNA analysis 
can be implemented in the clinical laboratory setting.
3.6. Validation of microarray results by qRT-PCR
miRNA microarrays are less expensive but inclined to have a lower sensitivity and dynamic 
range and are therefore best used as discovery tools rather than as quantitative assay plat-
forms. Current publication guidelines require that all microarray results are confirmed by 
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an independent gene expression profiling method. Most researchers choose qRT-PCR as 
the preferred method for the validation of microarray data using both TaqMan and SYBR-
green assay.
The TaqMan qRT-PCR method uses a stem-loop RT primer, specifically designed to detect 
the 3′ end of individual mature miRNAs generating a unique template for RT. In the qPCR 
step, cDNA is amplified with specific primers and product accumulation is monitored using 
a fluorogenic probe (TaqMan probe), complementary to the target gene. In SYBR-green-based 
qRT-PCR, miRNA is typically poly-adenylated at the 3′ end, and oligo-d(T) is used as an RT 
primer while a double-strand DNA binding dye (SYBR-green) allows for the detection of PCR 
products during qPCR.
We routinely use TaqMan® microRNA assays (Applied Biosystems, Inc.) to validate microar-
ray data on the same clinical samples as described [51] and perform qPCR in triplicate reac-
tions and the 2-ΔΔCt method to estimate the relative quantity of each miRNA [52]. An important 
issue is the choice of normalizer. Typically, “housekeeping” genes selected as endogenous 
controls allow normalization of qPCR data as they are affected by the same experimental vari-
ability as the target genes. In a cellular context, stable small RNA controls, such as RNU44, 
RNU48 and RNU6, are usually used. However, for circulating miRNAs, there is growing 
evidence that the abovementioned small RNAs are highly variable or not stably detectable 
[53]. This lack of consensus has resulted in the generation of various normalization strategies. 
An approach widely used and employed in our group is the selection, from each microarray 
study, of several genes as a normalizer based on their stable expression.
4. Conclusion
Circulating miRNAs are attractive as clinical biomarkers for diagnostic purposes, as well as 
for monitoring disease progression and response to treatment. However, the nature of cir-
culating miRNAs places several challenges. The success of the circulating miRNA profiling 
requires rigorous control of pre-analytic and analytic variables, specifically when investigat-
ing potential circulating miRNA markers. Here, we provided a consistent and reproducible 
method for circulating miRNA detection, profiling and analysis. We discussed the main 
issues associated with miRNA measurement that is crucial for miRNA profiling, especially 
for exosomal circulating miRNA. In addition, it needs to take into account that it is difficult to 
measure specific miRNA levels because they are short and conserved sequences, paralogs or 
distinguish between precursor and mature forms. In our work experience, the use of standard 
protocols for sample preparation, and of exogenous synthetic miRNA as the standard control, 
helps to solve a part of these problems. Microarray data processing such as normalization 
procedures among different samples is challenging especially for extracellular miRNA. In our 
work experience, it can be concluded that the use of robust algorithms and software may 
avoid errors and false positive discovery. However, the validation of array results by the use 
of an alternative methodology, especially when using different protocols and platforms for 
profiling purposes, is mandatory.
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Objective assessment of these technical metrics is an important step toward understanding 
the appropriate use of microarray technology application in general and more specifically for 
circulating miRNA to be used as clinical markers as well as in regulatory settings.
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